Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Masquelier, B; Neau, D; Chene, G; Larbere, J; Birac, V; Ragnaud, JM; Fleury, HJA
   Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA
   JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
   
   B. Masquelier et al., "Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA", J ACQ IMM D, 28(4), 2001, pp. 309-312
2. Skowron, G; Street, JC; Obee, EM
   Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy
   JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
   
   G. Skowron et al., "Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy", J ACQ IMM D, 28(4), 2001, pp. 313-319
3. Meroni, L; Manganaro, D; Varchetta, S; Gatti, N; Riva, A; Monforte, AD; Galli, M
   Maintenance of naive and Th1CD4 phenotype and lack of CD8 activation in patients switching from protease inhibitors to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimens
   JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
   
   L. Meroni et al., "Maintenance of naive and Th1CD4 phenotype and lack of CD8 activation in patients switching from protease inhibitors to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimens", J ACQ IMM D, 28(4), 2001, pp. 401-403
4. Knobel, H; Miro, TM; Domingo, P; Rivero, A; Marquez, M; Force, L; Gonzalez, A; De Miguel, V; Sanz, J; Boix, V; Blanco, JL; Locutura, J
   Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: A double-blind placebo- controlled trial: The GESIDA 09/99 study
   JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
   
   H. Knobel et al., "Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: A double-blind placebo- controlled trial: The GESIDA 09/99 study", J ACQ IMM D, 28(1), 2001, pp. 14-18
5. Manfredi, R
   A cross-sectional survey of HIV genotype mutations conferring resistance to all nonnucleoside reverse transcriptase inhibitors and related features, at the time of failure of antiretroviral therapy in the real world
   JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
   
   R. Manfredi, "A cross-sectional survey of HIV genotype mutations conferring resistance to all nonnucleoside reverse transcriptase inhibitors and related features, at the time of failure of antiretroviral therapy in the real world", J ACQ IMM D, 28(1), 2001, pp. 97-99
6. Rey, D; Schmitt, MP; Partisani, M; Hess-Kempf, G; Krantz, W; de Mautort, E; Bernard-Henry, C; Priester, M; Cheneau, C; Lang, JM
   Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: A median follow-up of 64 weeks
   JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
   
   D. Rey et al., "Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: A median follow-up of 64 weeks", J ACQ IMM D, 27(5), 2001, pp. 459-462
7. Ruiz, L; Negredo, E; Domingo, P; Paredes, R; Francia, E; Balague, M; Gel, S; Bonjoch, A; Fumaz, CR; Johnston, S; Romeu, J; Lange, J; Clotet, B
   Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy
   JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
   
   L. Ruiz et al., "Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy", J ACQ IMM D, 27(3), 2001, pp. 229-236
8. Jensen-Fangel, S; Thomsen, HF; Larsen, L; Black, FT; Obel, N
   The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients - A prospective, open-label, controlled, randomized study
   JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
   
   S. Jensen-Fangel et al., "The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients - A prospective, open-label, controlled, randomized study", J ACQ IMM D, 27(2), 2001, pp. 124-129
9. Gerber, JG; Rosenkranz, S; Segal, Y; Aberg, J; D'Amico, R; Mildvan, D; Gulick, R; Hughes, V; Flexner, C; Aweeka, F; Hsu, A; Gal, J
   Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: Results of AIDS clinical trials group (ACTG) 401
   JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
   
   J.G. Gerber et al., "Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: Results of AIDS clinical trials group (ACTG) 401", J ACQ IMM D, 27(2), 2001, pp. 153-160
10. Sabin, CA; Fisher, M; Churchill, D; Pozniak, A; Hay, P; Easterbrook, P; Williams, I
    Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    C.A. Sabin et al., "Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine", J ACQ IMM D, 26(5), 2001, pp. 462-465
11. Deeks, SG
    Nonnucleoside reverse transcriptase inhibitor resistance
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    S.G. Deeks, "Nonnucleoside reverse transcriptase inhibitor resistance", J ACQ IMM D, 26, 2001, pp. S25-S33
12. Dailly, E; Thomas, L; Kergueris, MF; Jolliet, P; Bourin, M
    High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavirand saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction
    JOURNAL OF CHROMATOGRAPHY B
    
    E. Dailly et al., "High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavirand saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction", J CHROMAT B, 758(2), 2001, pp. 129-135
13. Lopez, RM; Pou, L; Gomez, MR; Ruiz, I; Monterde, J
    Simple and rapid determination of nevirapine in human serum by reversed-phase high-performance liquid chromatography
    JOURNAL OF CHROMATOGRAPHY B
    
    R.M. Lopez et al., "Simple and rapid determination of nevirapine in human serum by reversed-phase high-performance liquid chromatography", J CHROMAT B, 751(2), 2001, pp. 371-376
14. Fan, B; Stewart, JT
    Determination of zidovudine/zalcitabine/nevirapine in human plasma by ion-pair HPLC
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
    
    B. Fan e J.T. Stewart, "Determination of zidovudine/zalcitabine/nevirapine in human plasma by ion-pair HPLC", J LIQ CHR R, 24(19), 2001, pp. 3017-3026
15. Maggiolo, F
    Comparison of NNRTIs in antiretroviral-experienced patients
    INTERNATIONAL JOURNAL OF STD & AIDS
    
    F. Maggiolo, "Comparison of NNRTIs in antiretroviral-experienced patients", INT J STD A, 12, 2001, pp. 10-17
16. Lafeuillade, A
    Factors affecting adherence and convenience in antiretroviral therapy
    INTERNATIONAL JOURNAL OF STD & AIDS
    
    A. Lafeuillade, "Factors affecting adherence and convenience in antiretroviral therapy", INT J STD A, 12, 2001, pp. 18-24
17. Treluyer, JM
    Pharmacology of antiretroviral agents in children
    ARCHIVES DE PEDIATRIE
    
    J.M. Treluyer, "Pharmacology of antiretroviral agents in children", ARCH PED, 8, 2001, pp. 242S-243S
18. Manfredi, R; Chiodo, F
    Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
    
    R. Manfredi e F. Chiodo, "Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease", INT J ANT A, 17(6), 2001, pp. 511-516
19. Mirochnick, M; Siminski, S; Fenton, T; Lugo, M; Sullivan, JL
    Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure
    PEDIATRIC INFECTIOUS DISEASE JOURNAL
    
    M. Mirochnick et al., "Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure", PEDIAT INF, 20(8), 2001, pp. 803-805
20. Zuber, B; Bottiger, D; Benthin, R; Ten Haaft, P; Heeney, J; Wahren, B; Oberg, B
    An in vivo model for HIV resistance development
    AIDS RESEARCH AND HUMAN RETROVIRUSES
    
    B. Zuber et al., "An in vivo model for HIV resistance development", AIDS RES H, 17(7), 2001, pp. 631-635
21. Clarke, SM; Mulcahy, FM; Tjia, J; Reynolds, HE; Gibbons, SE; Barry, MG; Back, DJ
    The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    S.M. Clarke et al., "The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz", BR J CL PH, 51(3), 2001, pp. 213-217
22. Veldkamp, AI; Weverling, GJ; Lange, JMA; Montaner, JSG; Reiss, P; Cooper, DA; Vella, S; Hall, D; Beijnen, JH; Hoetelmans, RMW
    High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals
    AIDS
    
    A.I. Veldkamp et al., "High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals", AIDS, 15(9), 2001, pp. 1089-1095
23. Shulman, N; Zolopa, AR; Passaro, D; Shafer, RW; Huang, W; Katzenstein, D; Israelski, DM; Hellmann, N; Petropoulos, C; Whitcomb, J
    Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy
    AIDS
    
    N. Shulman et al., "Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy", AIDS, 15(9), 2001, pp. 1125-1132
24. Eshleman, SH; Mracna, M; Guay, LA; Deseyve, M; Cunningham, S; Mirochnick, M; Musoke, P; Fleming, T; Fowler, MG; Mofenson, LM; Mmiro, F; Jackson, JB
    Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
    AIDS
    
    S.H. Eshleman et al., "Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)", AIDS, 15(15), 2001, pp. 1951-1957
25. Fagot, JP; Mockenhaupt, M; Bouwes-Bavinck, JN; Naldi, L; Viboud, C; Roujeau, JC
    Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
    AIDS
    
    J.P. Fagot et al., "Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis", AIDS, 15(14), 2001, pp. 1843-1848
26. Martinez, E; Arnedo, M; Giner, V; Gil, C; Caballero, M; Alos, L; Garcia, F; Holtzer, C; Mallolas, J; Miro, JM; Pumarola, T; Gatell, JM
    Lymphoid tissue viral burden and duration of viral suppression in plasma
    AIDS
    
    E. Martinez et al., "Lymphoid tissue viral burden and duration of viral suppression in plasma", AIDS, 15(12), 2001, pp. 1477-1482
27. Frater, AJ; Beardall, A; Ariyoshi, K; Churchill, D; Galpin, S; Clarke, JR; Weber, JN; McClure, MO
    Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients
    AIDS
    
    A.J. Frater et al., "Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients", AIDS, 15(12), 2001, pp. 1493-1502
28. Clumeck, N; Goebel, F; Rozenbaum, W; Gerstoft, J; Staszewski, S; Montaner, J; Johnson, M; Gazzard, B; Stone, C; Athisegaran, R; Moore, S
    Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
    AIDS
    
    N. Clumeck et al., "Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA", AIDS, 15(12), 2001, pp. 1517-1526
29. Walmsley, SL; Kelly, DV; Tseng, AL; Humar, A; Harrigan, PR
    Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy
    AIDS
    
    S.L. Walmsley et al., "Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy", AIDS, 15(12), 2001, pp. 1581-1584
30. Bartlett, JA; DeMasi, R; Quinn, J; Moxham, C; Rousseau, F
    Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults
    AIDS
    
    J.A. Bartlett et al., "Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults", AIDS, 15(11), 2001, pp. 1369-1377
31. Martinez, E; Blanco, JL; Arnaiz, JA; Perez-Cuevas, JB; Mocroft, A; Cruceta, A; Marcos, MA; Milinkovic, A; Garcia-Viejo, MA; Mallolas, J; Carne, X; Phillips, A; Gatell, JM
    Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
    AIDS
    
    E. Martinez et al., "Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy", AIDS, 15(10), 2001, pp. 1261-1268
32. Conway, B; Wainberg, MA; Hall, D; Harris, M; Reiss, P; Cooper, D; Vella, S; Curry, R; Robinson, P; Lange, JMA; Montaner, JSG
    Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine
    AIDS
    
    B. Conway et al., "Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine", AIDS, 15(10), 2001, pp. 1269-1274
33. Veldkamp, AI; van Heeswijk, RPG; Mulder, JW; Meenhorst, PL; Hoetelmans, RMW; Lange, JMA; Beijnen, JH
    Limited sampling strategies for the estimation of the systemic exposure tothe HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine
    THERAPEUTIC DRUG MONITORING
    
    A.I. Veldkamp et al., "Limited sampling strategies for the estimation of the systemic exposure tothe HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine", THER DRUG M, 23(6), 2001, pp. 606-611
34. Bart, PA; Rizzardi, PG; Gallant, S; Golay, KP; Baumann, P; Pantaleo, G; Eap, CB
    Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir
    THERAPEUTIC DRUG MONITORING
    
    P.A. Bart et al., "Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir", THER DRUG M, 23(5), 2001, pp. 553-555
35. van Heeswijk, RPG; Veldkamp, AI; Mulder, JW; Meenhorst, PL; Beijnen, JH; Lange, JMA; Hoetelmans, RMW
    Saliva as an alternative body fluid for therapeutic drug monitoring of thenonnucleoside reverse transcription inhibitor nevirapine
    THERAPEUTIC DRUG MONITORING
    
    R.P.G. van Heeswijk et al., "Saliva as an alternative body fluid for therapeutic drug monitoring of thenonnucleoside reverse transcription inhibitor nevirapine", THER DRUG M, 23(3), 2001, pp. 255-258
36. Hetherington, S; McGuirk, S; Powell, G; Cutrell, A; Naderer, O; Spreen, B; Lafon, S; Pearce, G; Steel, H
    Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir
    CLINICAL THERAPEUTICS
    
    S. Hetherington et al., "Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir", CLIN THER, 23(10), 2001, pp. 1603-1614
37. Delaugerre, C; Rohban, R; Simon, A; Mouroux, M; Tricot, C; Agher, R; Huraux, JM; Katlama, C; Calvez, V
    Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen
    JOURNAL OF MEDICAL VIROLOGY
    
    C. Delaugerre et al., "Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen", J MED VIROL, 65(3), 2001, pp. 445-448
38. von Moltke, LL; Greenblatt, DJ; Granda, BW; Giancarlo, GM; Duan, SX; Daily, JP; Harmatz, JS; Shader, RI
    Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors
    JOURNAL OF CLINICAL PHARMACOLOGY
    
    L.L. von Moltke et al., "Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors", J CLIN PHAR, 41(1), 2001, pp. 85-91
39. Buckheit, RW; Watson, K; Fliakas-Boltz, V; Russell, J; Loftus, TL; Osterling, MC; Turpin, JA; Pallansch, LA; White, EL; Lee, JW; Lee, SH; Oh, JW; Kwon, HS; Chung, SG; Cho, EH
    SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    
    R.W. Buckheit et al., "SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2", ANTIM AG CH, 45(2), 2001, pp. 393-400
40. Sullivan, JL; Luzuriaga, K
    The changing face of pediatric HIV-1 infection
    NEW ENGLAND JOURNAL OF MEDICINE
    
    J.L. Sullivan e K. Luzuriaga, "The changing face of pediatric HIV-1 infection", N ENG J MED, 345(21), 2001, pp. 1568-1569
41. Maga, G; Ramunno, A; Nacci, V; Locatelli, GA; Spadari, S; Fiorini, I; Baldanti, F; Paolucci, S; Zavattoni, M; Bergamini, A; Galletti, B; Muck, S; Hubscher, U; Giorgi, G; Guiso, G; Caccia, S; Campiani, G
    The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464 - A novel generation of nonnucleoside inhibitors
    JOURNAL OF BIOLOGICAL CHEMISTRY
    
    G. Maga et al., "The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464 - A novel generation of nonnucleoside inhibitors", J BIOL CHEM, 276(48), 2001, pp. 44653-44662
42. Claudio, GA; Martin, AF; Perrino, SD; Velasco, AA
    DRESS syndrome associated with novirapine therapy
    ARCHIVES OF INTERNAL MEDICINE
    
    G.A. Claudio et al., "DRESS syndrome associated with novirapine therapy", ARCH IN MED, 161(20), 2001, pp. 2501-2502
43. Nieuwkerk, PT; Sprangers, MAG; Burger, DM; Hoetelmans, RMW; Hugen, PWH; Danner, SA; van der Ende, ME; Schneider, MME; Schrey, G; Meenhorst, PL; Sprenger, HG; Kauffmann, RH; Jambroes, M; Chesney, MA; de Wolf, F; Lange, JMA
    Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study
    ARCHIVES OF INTERNAL MEDICINE
    
    P.T. Nieuwkerk et al., "Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study", ARCH IN MED, 161(16), 2001, pp. 1962-1968
44. Stewart, KA
    Toward a historical perspective on sexuality in Uganda: The reproductive lifeline technique for grandmothers and their daughters
    AFRICA TODAY
    
    K.A. Stewart, "Toward a historical perspective on sexuality in Uganda: The reproductive lifeline technique for grandmothers and their daughters", AFR TODAY, 47(3-4), 2001, pp. 122-148
45. Torti, C; Pozniak, A; Nelson, M; Hertogs, K; Gazzard, BG
    Distribution of K103N and/or Y181CHIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
    
    C. Torti et al., "Distribution of K103N and/or Y181CHIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors", J ANTIMICRO, 48(1), 2001, pp. 113-116
46. Stringer, JSA; Rouse, DJ; Vermund, SH; Goldenberg, RL; Sinkala, M; Stinnett, AA
    Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    J.S.A. Stringer et al., "Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa", J ACQ IMM D, 24(4), 2000, pp. 369-377
47. Rainey, PM; Friedland, G; McCance-Katz, EF; Andrews, L; Mitchell, SM; Charles, C; Jatlow, P
    Interaction of methadone with didanosine and stavudine
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    P.M. Rainey et al., "Interaction of methadone with didanosine and stavudine", J ACQ IMM D, 24(3), 2000, pp. 241-248
48. Shulman, NS; Zolopa, AR; Passaro, DJ; Murlidharan, U; Israelski, DM; Brosgart, CL; Miller, MD; Van Doren, S; Shafer, RW; Katzenstein, DA
    Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
    
    N.S. Shulman et al., "Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response", J ACQ IMM D, 23(3), 2000, pp. 221-226
49. Hollanders, RMF; Kolmer, EWJV; Burger, DM; Wuis, EW; Koopmans, PP; Hekster, YA
    Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptaseinhibitor, in human plasma by reversed-phase high-performance liquid chromatography
    JOURNAL OF CHROMATOGRAPHY B
    
    R.M.F. Hollanders et al., "Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptaseinhibitor, in human plasma by reversed-phase high-performance liquid chromatography", J CHROMAT B, 744(1), 2000, pp. 65-71
50. Darbyshire, J
    Therapeutic interventions in HIV infection - a critical view
    TROPICAL MEDICINE & INTERNATIONAL HEALTH
    
    J. Darbyshire, "Therapeutic interventions in HIV infection - a critical view", TR MED I H, 5(7), 2000, pp. A26-A31
51. Wit, FWNM
    Experience with nevirapine in previously treated HIV-1-infected individuals
    ANTIVIRAL THERAPY
    
    F.W.N.M. Wit, "Experience with nevirapine in previously treated HIV-1-infected individuals", ANTIVIR TH, 5(4), 2000, pp. 257-266
52. Hogberg, M; Morrison, I
    HIV-1 non-nucleoside reverse transcriptase inhibitors
    EXPERT OPINION ON THERAPEUTIC PATENTS
    
    M. Hogberg e I. Morrison, "HIV-1 non-nucleoside reverse transcriptase inhibitors", EXPERT OP T, 10(8), 2000, pp. 1189-1199
53. Palomares, JC; Perea, EJ; Terrero, E; Torres, JM; Garcia, ML; Romero, J; Alejo, A
    Detection of resistant mutations in the reverse transcriptase of HIV-1-infected children
    CLINICAL MICROBIOLOGY AND INFECTION
    
    J.C. Palomares et al., "Detection of resistant mutations in the reverse transcriptase of HIV-1-infected children", CL MICRO IN, 6(5), 2000, pp. 268-270
54. Chen, F; Pau, AK; Piscitelli, SC
    Update on preventing vertical transmission of HIV type 1
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    
    F. Chen et al., "Update on preventing vertical transmission of HIV type 1", AM J HEAL S, 57(17), 2000, pp. 1616-1623
55. Gangar, M; Arias, G; O'Brien, JG; Kemper, CA
    Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine
    ANNALS OF PHARMACOTHERAPY
    
    M. Gangar et al., "Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine", ANN PHARMAC, 34(7-8), 2000, pp. 839-842
56. Rieder, MJ; Dekaban, GA
    Deja vu all over again: Adverse reactions to nonnucleoside reverse transcriptase inhibitors
    ANNALS OF PHARMACOTHERAPY
    
    M.J. Rieder e G.A. Dekaban, "Deja vu all over again: Adverse reactions to nonnucleoside reverse transcriptase inhibitors", ANN PHARMAC, 34(7-8), 2000, pp. 940-942
57. Piroth, L; Grappin, M; Sgro, C; Buisson, M; Duong, M; Chavanet, P
    Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV-coinfected patient
    ANNALS OF PHARMACOTHERAPY
    
    L. Piroth et al., "Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV-coinfected patient", ANN PHARMAC, 34(4), 2000, pp. 534-535
58. Raffi, F; Bonnet, B; Ferre, V; Esnault, JL; Perre, P; Reliquet, V; Leautez, S; Bouillant, C; Vergnoux, O; Weinbreck, P
    Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA
    CLINICAL INFECTIOUS DISEASES
    
    F. Raffi et al., "Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA", CLIN INF D, 31(5), 2000, pp. 1274-1278
59. Bossi, P; Colin, D; Bricaire, F; Caumes, E
    Hypersensitivity syndrome associated with efavirenz therapy
    CLINICAL INFECTIOUS DISEASES
    
    P. Bossi et al., "Hypersensitivity syndrome associated with efavirenz therapy", CLIN INF D, 30(1), 2000, pp. 227-228
60. Gerber, JG
    Using pharmacokinetics to optimize antiretroviral drug-drug interactions the treatment of human immunodeficiency virus infection
    CLINICAL INFECTIOUS DISEASES
    
    J.G. Gerber, "Using pharmacokinetics to optimize antiretroviral drug-drug interactions the treatment of human immunodeficiency virus infection", CLIN INF D, 30, 2000, pp. S123-S129
61. Harris, M; Montaner, JSG
    Clinical uses of non-nucleoside reverse transcriptase inhibitors
    REVIEWS IN MEDICAL VIROLOGY
    
    M. Harris e J.S.G. Montaner, "Clinical uses of non-nucleoside reverse transcriptase inhibitors", REV MED VIR, 10(4), 2000, pp. 217-229
62. Ren, J; Milton, J; Weaver, KL; Short, SA; Stuart, DI; Stammers, DK
    Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase
    STRUCTURE
    
    J. Ren et al., "Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase", STRUCTURE, 8(10), 2000, pp. 1089-1094
63. Luo, CW
    Strategies for prevention of mother-to-child transmission of HIV
    REPRODUCTIVE HEALTH MATTERS
    
    C.W. Luo, "Strategies for prevention of mother-to-child transmission of HIV", REPROD H M, 8(16), 2000, pp. 144-155
64. Hankins, C
    Preventing mother-to-child transmission of HIV in developing countries: Recent developments and ethical implications
    REPRODUCTIVE HEALTH MATTERS
    
    C. Hankins, "Preventing mother-to-child transmission of HIV in developing countries: Recent developments and ethical implications", REPROD H M, 8(15), 2000, pp. 87-92
65. Hogberg, M; Engelhardt, P; Vrang, L; Zhang, H
    Bioisosteric modification of PETT-HIV-1 RT-inhibitors: Synthesis and biological evaluation
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    
    M. Hogberg et al., "Bioisosteric modification of PETT-HIV-1 RT-inhibitors: Synthesis and biological evaluation", BIOORG MED, 10(3), 2000, pp. 265-268
66. Clarke, S; Harrington, P; Condon, C; Kelleher, D; Smith, OP; Mulcahy, F
    Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy
    INTERNATIONAL JOURNAL OF STD & AIDS
    
    S. Clarke et al., "Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy", INT J STD A, 11(5), 2000, pp. 336-337
67. Kishimoto, W; Takano, J; Senda, C; Ishiguro, N; Sakai, K; Igarashi, T
    Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats
    BIOLOGICAL & PHARMACEUTICAL BULLETIN
    
    W. Kishimoto et al., "Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats", BIOL PHAR B, 23(9), 2000, pp. 1027-1032
68. De Clercq, E
    Structures and activities of non-nucleoside reverse transcriptase inhibitors (NNRTIs).
    MEDECINE ET MALADIES INFECTIEUSES
    
    E. De Clercq, "Structures and activities of non-nucleoside reverse transcriptase inhibitors (NNRTIs).", MED MAL INF, 30(7), 2000, pp. 421-430
69. Khaliq, Y; Gallicano, K; Seguin, I; Fyke, K; Carignan, G; Bulman, D; Badley, A; Cameron, DW
    Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    
    Y. Khaliq et al., "Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease", BR J CL PH, 50(2), 2000, pp. 108-115
70. Manfredi, R; Chiodo, F
    First-line nevirapine in combination with nucleoside analogues compared with nevirapine added to a salvage HAART
    INFECTION
    
    R. Manfredi e F. Chiodo, "First-line nevirapine in combination with nucleoside analogues compared with nevirapine added to a salvage HAART", INFECTION, 28(3), 2000, pp. 167-170
71. van Heeswijk, RPG; Veldkamp, AI; Mulder, JW; Meenhorst, PL; Wit, FWNM; Lange, JMA; Danner, SA; Foudraine, NA; Kwakkelstein, MO; Reiss, P; Beijnen, JH; Hoetelmans, RMW
    The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
    AIDS
    
    R.P.G. van Heeswijk et al., "The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals", AIDS, 14(8), 2000, pp. F77-F82
72. Wegner, SA; Brodine, SK; Mascola, JR; Tasker, SA; Shaffer, RA; Starkey, MJ; Barile, A; Martin, GJ; Aronson, N; Emmons, WW; Stephan, K; Bloor, S; Vingerhoets, J; Hertogs, K; Larder, B
    Prevalence of genotypic and phenotypic resistance to anti-retroviral drugsin a cohort of therapy-naive HIV-1 infected US military personnel
    AIDS
    
    S.A. Wegner et al., "Prevalence of genotypic and phenotypic resistance to anti-retroviral drugsin a cohort of therapy-naive HIV-1 infected US military personnel", AIDS, 14(8), 2000, pp. 1009-1015
73. Barreiro, P; Soriano, V; Blanco, F; Casimiro, C; de la Cruz, JJ; Gonzalez-Lahoz, J
    Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
    AIDS
    
    P. Barreiro et al., "Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy", AIDS, 14(7), 2000, pp. 807-812
74. Casado, JL; Hertogs, K; Ruiz, L; Dronda, F; Van Cauwenberge, A; Arno, A; Garcia-Arata, I; Bloor, S; Bonjoch, A; Blazquez, J; Clotet, B; Larder, B
    Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen
    AIDS
    
    J.L. Casado et al., "Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen", AIDS, 14(2), 2000, pp. F1-F7
75. Zhou, XJ; Havlir, DV; Richman, DD; Acosta, EP; Hirsch, M; Collier, AC; Tebas, P; Sommadossi, JP
    Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients
    AIDS
    
    X.J. Zhou et al., "Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients", AIDS, 14(18), 2000, pp. 2869-2876
76. Garcia, F; Knobel, H; Sambeat, MA; Arrizabalaga, J; Aranda, M; Romeu, J; Dalmau, D; Segura, F; Gomez-Sirvent, JL; Ferrer, E; Cruceta, A; Gallart, T; Pumarola, T; Miro, JM; Gatell, JM
    Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study
    AIDS
    
    F. Garcia et al., "Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study", AIDS, 14(16), 2000, pp. 2485-2494
77. Barreiro, P; Soriano, V; Casas, E; Estrada, V; Tellez, MJ; Hoetelmans, R; de Requena, DG; Jimenez-Nacher, I; Gonzalez-Lahoz, J
    Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids
    AIDS
    
    P. Barreiro et al., "Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids", AIDS, 14(14), 2000, pp. 2153-2157
78. Taylor, S; van Heeswijk, RPG; Hoetelmans, RMW; Workman, J; Drake, SM; White, DJ; Pillay, D
    Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men
    AIDS
    
    S. Taylor et al., "Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men", AIDS, 14(13), 2000, pp. 1979-1984
79. Kuritzkes, DR; Bassett, RL; Johnson, VA; Marschner, IC; Eron, JJ; Sommadossi, JP; Acosta, EP; Murphy, RL; Fife, K; Wood, K; Bell, D; Martinez, A; Pettinelli, CB
    Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370
    AIDS
    
    D.R. Kuritzkes et al., "Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370", AIDS, 14(11), 2000, pp. 1553-1561
80. Precious, HM; Gunthard, HF; Wong, JK; D'Aquila, RT; Johnson, VA; Kuritzkes, DR; Richman, DD; Brown, AJL
    Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy
    AIDS
    
    H.M. Precious et al., "Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy", AIDS, 14(1), 2000, pp. 31-36
81. Merchant, RC
    Nonoccupational HIV postexposure prophylaxis: A new role for the emergencydepartment
    ANNALS OF EMERGENCY MEDICINE
    
    R.C. Merchant, "Nonoccupational HIV postexposure prophylaxis: A new role for the emergencydepartment", ANN EMERG M, 36(4), 2000, pp. 366-375
82. Pirounaki, M; Vander Heyden, NA; Arens, M; Ratner, L
    Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line
    JOURNAL OF VIROLOGICAL METHODS
    
    M. Pirounaki et al., "Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line", J VIROL MET, 85(1-2), 2000, pp. 151-161
83. Sweat, M; Gregorich, S; Sangiwa, G; Furlonge, C; Balmer, D; Kamenga, C; Grinstead, O; Coates, T
    Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania
    LANCET
    
    M. Sweat et al., "Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania", LANCET, 356(9224), 2000, pp. 113-121
84. Wood, E; Braitstein, P; Montaner, JSG; Schechter, MT; Tyndall, MW; O'Shaughnessy, MV; Hogg, RS
    Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa
    LANCET
    
    E. Wood et al., "Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa", LANCET, 355(9221), 2000, pp. 2095-2100
85. Taylor, GP; Lyall, EGH; Back, D; Ward, C; Tudor-Williams, G
    Pharmacological implications of lengthened in-utero exposure to nevirapine
    LANCET
    
    G.P. Taylor et al., "Pharmacological implications of lengthened in-utero exposure to nevirapine", LANCET, 355(9221), 2000, pp. 2134-2135
86. Carpenter, CCJ; Cooper, DA; Fischl, MA; Gatell, JM; Gazzard, BG; Hammer, SM; Hirsch, MS; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Saag, MS; Schechter, M; Schooley, RT; Vella, S; Yeni, PG; Volberding, PA
    Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    
    C.C.J. Carpenter et al., "Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel", J AM MED A, 283(3), 2000, pp. 381-390
87. Bacheler, LT; Anton, ED; Kudish, P; Baker, D; Bunville, J; Krakowski, K; Bolling, L; Aujay, M; Wang, XV; Ellis, D; Becker, MF; Lasut, AL; George, HJ; Spalding, DR; Hollis, G; Abremski, K
    Human immunodeficiency virus type 1 mutations selected in patients failingefavirenz combination therapy
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    
    L.T. Bacheler et al., "Human immunodeficiency virus type 1 mutations selected in patients failingefavirenz combination therapy", ANTIM AG CH, 44(9), 2000, pp. 2475-2484
88. Maga, G; Ubiali, D; Salvetti, R; Pregnolato, M; Spadari, S
    Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    
    G. Maga et al., "Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes", ANTIM AG CH, 44(5), 2000, pp. 1186-1194
89. Hertogs, K; Bloor, S; De Vroey, V; Van den Eynde, C; Dehertogh, P; Van Cauwenberge, A; Sturmer, M; Alcorn, T; Wegner, S; Van Houtte, M; Miller, V; Larder, BA
    A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    
    K. Hertogs et al., "A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V", ANTIM AG CH, 44(3), 2000, pp. 568-573
90. Joly, V; Moroni, M; Concia, E; Lazzarin, A; Hirschel, B; Jost, J; Chiodo, F; Bentwich, Z; Love, WC; Hawkins, DA; Wilkins, EGL; Gatell, AJ; Vetter, N; Greenwald, C; Freimuth, WW; De Cian, W
    Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    
    V. Joly et al., "Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial", ANTIM AG CH, 44(11), 2000, pp. 3155-3157
91. Sibaud, V; Billon, C; Barcat, D; Bernard, N; Geniaux, M
    Hypersensitivity syndrome associated with nevirapine therapy
    THERAPIE
    
    V. Sibaud et al., "Hypersensitivity syndrome associated with nevirapine therapy", THERAPIE, 55(2), 2000, pp. 320-322
92. Pedersen, OS; Pedersen, EB
    The flourishing syntheses of non-nucleoside reverse transcriptase inhibitors
    SYNTHESIS-STUTTGART
    
    O.S. Pedersen e E.B. Pedersen, "The flourishing syntheses of non-nucleoside reverse transcriptase inhibitors", SYNTHESIS-S, (4), 2000, pp. 479-495
93. McIntyre, J; Gray, G
    Antiretroviral treatment to prevent mother-to-child transmission of HIV-1
    SOUTH AFRICAN JOURNAL OF SCIENCE
    
    J. McIntyre e G. Gray, "Antiretroviral treatment to prevent mother-to-child transmission of HIV-1", S AFR J SCI, 96(6), 2000, pp. 277-280
94. Hayashi, T
    New therapy reduces AIDS passed to fetuses and costs less
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
    
    T. Hayashi, "New therapy reduces AIDS passed to fetuses and costs less", YAKUGAKU ZA, 120(8), 2000, pp. 683-687
95. Dona, C; Soriano, V; Barreiro, P; Jimenez-Nacher, I; Gonzalez-Lahoz, J
    Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program
    MEDICINA CLINICA
    
    C. Dona et al., "Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program", MED CLIN, 115(9), 2000, pp. 337-338
96. Fernandez, DG; Briones, VGP; Sanchez, JM; Rodellas, AC
    Stevens-Johnson Syndrome associated with nevirapine
    REVISTA CLINICA ESPANOLA
    
    D.G. Fernandez et al., "Stevens-Johnson Syndrome associated with nevirapine", REV CLIN ES, 200(3), 2000, pp. 179-180
97. Munoz, RP; Gonzalez, JS; Garcia, RB; Solero, MM
    Necrotic plaques in patient with chronic renal failure
    REVISTA CLINICA ESPANOLA
    
    R.P. Munoz et al., "Necrotic plaques in patient with chronic renal failure", REV CLIN ES, 200(11), 2000, pp. 635-636
98. Rodrigo, MDB; Rodriguez, MA; Garcia, MLL; Llera, JLG
    Nevirapine induces abstinence symptoms among HIV-infected patients on a methadone maintenance programme
    REVISTA CLINICA ESPANOLA
    
    M.D.B. Rodrigo et al., "Nevirapine induces abstinence symptoms among HIV-infected patients on a methadone maintenance programme", REV CLIN ES, 200(1), 2000, pp. 12-14
99. Joly, V; Yeni, P
    Non-nucleosidic reverse transcriptase inhibitors
    ANNALES DE MEDECINE INTERNE
    
    V. Joly e P. Yeni, "Non-nucleosidic reverse transcriptase inhibitors", ANN MED IN, 151(4), 2000, pp. 260-267
100. Regazzi, MB; Villani, P; Maserati, R; Seminari, E; Pan, A; LoCaputo, F; Gambarana, E; Fiocchi, C
     Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients
     JAC. Journal of antimicrobial chemotherapy
     
     M.B. Regazzi et al., "Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients", J ANTIMICRO, 45(3), 2000, pp. 343-347